Latest news about Samrat Pharmachem
Samrat Pharmachem
209.10
+1.75(+0.84%)
Company Performance:
View Company Insights1D+0.84%
1M-0.95%
6M-20.16%
1Y-40.69%
5Y-13.45%
More news about Samrat Pharmachem
18Feb 26
Samrat Pharmachem Reports Q3 FY26 Loss of Rs 45.95 Lakhs Against Prior Year Profit
Samrat Pharmachem Limited reported a net loss of Rs 45.95 lakhs for Q3 FY26 compared to a profit of Rs 278.48 lakhs in Q3 FY25, marking a significant deterioration in financial performance. For the nine-month period, the company posted a loss of Rs 127.57 lakhs against a profit of Rs 751.14 lakhs in the previous year. Despite the challenging profitability metrics, total income from operations remained relatively stable at Rs 6,382.71 lakhs for the quarter. The results were approved by the Board of Directors on February 13, 2026, and published in compliance with regulatory requirements.
15Nov 25
Samrat Pharmachem Reports Q2 FY26 Loss Despite Revenue Growth
Samrat Pharmachem Limited, a pharmaceutical chemicals manufacturer, released Q2 FY26 results ending September 30, 2025. Revenue increased by 10% to Rs. 7,887.03 lakhs, but the company reported a net loss of Rs. 58.73 lakhs. For the half-year, losses widened to Rs. 81.62 lakhs compared to a profit of Rs. 472.66 lakhs in the previous year. The half-year EPS stood at negative Rs. 2.64. The company continues to operate in a single business segment of pharmaceutical chemicals manufacturing.
25Jul 25
Samrat Pharmachem Reappoints Key Executives, Maintaining Family Leadership
Samrat Pharmachem Limited has announced the reappointment of three key executives for five-year terms, effective April 1, 2026, subject to shareholder approval. Lalit Mehta (88) will continue as Chairman & Managing Director, Rajesh Mehta (61) as Executive Director, and Megh Mehta (32) as Executive Director. The reappointments aim to maintain leadership continuity and leverage their extensive industry experience. The board will consist of seven directors, including three executive directors and four independent non-executive directors, balancing family leadership with independent oversight.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Zydus Life Science
Dr Reddys Laboratories
Lupin
Mankind Pharma
Aurobindo Pharma
Laurus Labs
1,780.10
(-0.47%)
6,596.50
(+0.30%)
4,339.90
(-0.65%)
1,398.70
(+1.71%)
1,084.60
(+0.74%)
1,267.50
(+0.33%)
2,249.80
(-0.50%)
2,353.00
(-0.70%)
1,463.60
(+1.61%)
1,427.20
(+2.36%)
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
